ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025
Plasminogen Activator Inhibitor 1 in Patients with Primary Immune Thrombocytopenia: A Case Control Study.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Haemostasis alterations in immune thrombocytopenia and their clinical significance.Research and practice in thrombosis and haemostasis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary immune thrombocytopenia (ITP) is a condition associated with decreased platelet count plus subsequent high risk of bleeding. Many studies mentioned that ITP also has a higher risk of developing thrombosis, which may have a significant influence on the disease management. Plasminogen activator inhibitor-1 (PAI-1), a fibrinolysis inhibitor, is implicated within the procoagulant state of ITP patients. To assess the PAI-1 serum level in ITP patients, non-immunologic thrombocytopenia controls (TC) and healthy controls (HC), and to correlate PAI-1 level with clinical variables. Serum PAI-1 was measured by ELISA in 45 ITP patients, 22 TC and 22 HC. All participants were subjected to complete clinical assessment and examination. Bleeding severity was assessed using SMOG bleeding score. Levels of PAI- 1 were discovered to be significantly higher in ITP patients compared to TC and HC with a high significant difference between the three groups with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.